DEPRESSION AND COGNITIVE DISTURBANCES: EXPERIENCE OF VORTIOXETINE USE IN NEUROLOGIC PRACTICE
https://doi.org/10.21518/2079-701X-2017-11-36-39
Abstract
The article provides an experience of use of the new antidepressant with the precognitive action – Vortioxetine. High therapy compliance was demonstrated. The drug is effective in relief of depression, improves cognitive functions in neurologic patients and presumably has pain-killing action.
References
1. Alexopoulos GS, Borson S, Cuthbert BN. Assessment of late life depression. Biol Psychiatry, 2002, 52(3): 164-74.
2. Alvarez E, Perez V, Dragheim M, et al. A doubleblind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol, 2012, 15(5): 589-600.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.
4. Fehnel SE, Forsyth BH, DiBenedetti DB, et al. Patient-centered assessment of cognitive symptoms of depression. CNS Spectr, 2016, 21(1): 43-52.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960, 23: 56-62.
6. Helman AM, Murphy MP. Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo. Biochim Biophys Acta, 2015. S0925-4439(15)00363-4.
7. Iverson GL, Lam RW. Rapid screening for perceived cognitive impairment in major depressive disorder. Ann Clin Psychiatry, 2013, 25(2): 135-40.
8. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetinereferenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol, 2012, 27(4): 215-23.
9. Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry, 2014, 59(12): 649-54.
10. Lee HB, Lyketsos CG. Depression in Alzheimer’s disease: heterogeneity and related issues. Biol Psychiatry, 2003, 54(3): 353-6
11. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol, 2014, 17(10): 1557-67.
12. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ, 1992, 305: 1198-202.
13. WHO. The ICD-10 Classification of Mental and Behavioural Disorder: Clinical descriptions and diagnostic guidelines. F10-F19.
Review
For citations:
Azimova YE. DEPRESSION AND COGNITIVE DISTURBANCES: EXPERIENCE OF VORTIOXETINE USE IN NEUROLOGIC PRACTICE. Meditsinskiy sovet = Medical Council. 2017;(11):36-39. https://doi.org/10.21518/2079-701X-2017-11-36-39
Views:
889
Email this article 